Elstein Amir 4

What Happened

• Amir Elstein, a director of Teva Pharmaceutical Industries Ltd (TEVA), had 14,492 derivative awards convert to ordinary shares on June 5, 2026 (transaction code M). The filing shows an acquisition/conversion of 14,492 shares and a simultaneous disposition of 14,492 shares at $0.00. No cash proceeds or dollar value for the conversion were reported in the Form 4.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (filed within the normal 2-business-day window).
• Reported activity: 14,492 shares acquired via conversion/exercise of derivative; 14,492 shares disposed at $0.00.
• Price/Value: Acquisition price reported as N/A; disposition price reported as $0.00 (no cash proceeds reported).
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share).
  • F2: Each restricted share unit (RSU) represents a contingent right to one ordinary share or cash at settlement.
  • F3: These RSUs were granted June 5, 2025 and vested June 5, 2026.
• No 10b5-1 plan or late-filing indication was reported.

Context

• This was a derivative conversion/RSU vesting event, not an open-market purchase or sale. The reported disposition at $0.00 typically reflects a net share settlement or shares withheld/used in connection with settlement obligations (e.g., taxes), rather than a market sale that generated cash for the insider. Awards and vested RSUs are routine compensation and do not by themselves indicate the insider's view on the stock.